FARGION, SILVIA ROSSANA
FARGION, SILVIA ROSSANA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors
2024 R. Lombardi, A. Mantovani, A. Cespiati, P. Francione, G. Maffi, E. Del Zanna, C. Maffeis, A. Colecchia, N. Passigato, A. Ferrarese, C.D. Cusumanu, R. Villani, E. Orsi, V. Grancini, L. Airaghi, D. Bignamini, G. Serviddio, G. Targher, P. Dongiovanni, S. Fargion, A.L. Fracanzani
Recreating gut-liver axis during NAFLD onset by using a Caco-2/HepG2 co-culture system
2022 M. Meroni, E. Paolini, M. Longo, R. Piciotti, G. Tria, S. Fargion, A. Ludovica Fracanzani, P. Dongiovanni
{PD}-1/{PD}-L1 Immuno-Mediated Therapy in {NAFLD}: Advantages and Obstacles in the Treatment of Advanced Disease
2022 R. Lombardi, R. Piciotti, P. Dongiovanni, M. Meroni, S.R. Fargion, A.L. Fracanzani
Interaction between lifestyle changes and PNPLA3 genotype in NAFLD patients during the COVID-19 lockdown
2022 F. Cinque, A. Cespiati, R. Lombardi, A. Costantino, G. Maffi, F. Alletto, L. Colavolpe, P. Francione, G. Oberti, E. Fatta, C. Bertelli, G. Sigon, P. Dongiovanni, M. Vecchi, S. Fargion, A.L. Fracanzani
Genetics, immunity and nutrition boost the switching from nash to hcc
2021 P. Dongiovanni, M. Meroni, M. Longo, S. Fargion, A.L. Fracanzani
Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD
2021 E. Corradini, E. Buzzetti, P. Dongiovanni, S. Scarlini, A. Caleffi, S. Pelusi, I. Bernardis, P. Ventura, R. Rametta, E. Tenedini, E. Tagliafico, A.L. Fracanzani, S. Fargion, A. Pietrangelo, L. Valenti
Cardiovascular involvement after liver transplantation: role of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
2021 R. Lombardi, G. Pisano, S. Fargion, A.L. Fracanzani
Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP)
2021 A. Cespiati, S. Petta, R. Lombardi, V. Di Marco, V. Calvaruso, C. Bertelli, G. Pisano, E. Fatta, G. Sigon, F. Iuculano, L. Crapanzano, G. Gibilaro, P. Francione, A. Craxì, S. Fargion, A.L. Fracanzani
MAFLD and NAFLD: is there the need for redefining the risk of cardiovascular disease and mortality?
2021 R. Lombardi, A. Cespiati, P. Francione, F. Cinque, S. Fargion, A.L. Fracanzani
Dysmetabolic hyperferritinemia and dysmetabolic iron overload syndrome (Dios): Two related conditions or different entities?
2020 R. Rametta, A.L. Fracanzani, S. Fargion, P. Dongiovanni
Impact of natural neuromedin-B receptor variants on iron metabolism
2020 R. Rametta, P. Dongiovanni, G.A. Baselli, S. Pelusi, M. Meroni, A.L. Fracanzani, F. Busti, A. Castagna, S. Scarlini, E. Corradini, A. Pietrangelo, D. Girelli, S. Fargion, L. Valenti
Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD
2020 P. Dongiovanni, M. Meroni, S. Petta, M. Longo, A. Alisi, G. Soardo, L. Valenti, L. Miele, S. Grimaudo, G. Pennisi, G. Antonio, D. Consonni, S. Fargion, A.L. Fracanzani
High prevalence of early atherosclerotic and cardiac damage in patients undergoing liver transplantation : preliminary results
2020 G. Pisano, M.F. Donato, D. Consonni, G. Oberti, V. Borroni, R. Lombardi, F. Invernizzi, C. Bertelli, L. Caccamo, M. Porzio, D. Dondossola, G. Rossi, S. Fargion, A.L. Fracanzani
Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes
2020 R. Lombardi, L. Airaghi, G. Targher, G. Serviddio, G. Maffi, A. Mantovani, C. Maffeis, A. Colecchia, R. Villani, L. Rinaldi, E. Orsi, G. Pisano, L.E. Adinolfi, S. Fargion, A.L. Fracanzani
FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage
2020 R. Lombardi, S. Petta, G. Pisano, P. Dongiovanni, L. Rinaldi, L.E. Adinolfi, C. Acierno, L. Valenti, R. Boemi, F. Spatola, A. Craxi, S. Fargion, A.L. Fracanzani
Liver involvement in Gaucher disease : a practical review for the hepatologist and the gastroenterologist
2020 F. Carubbi, M.D. Cappellini, S. Fargion, A.L. Fracanzani, F. Nascimbeni
NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes
2020 R. Lombardi, L. Airaghi, G. Targher, G. Serviddio, G. Maffi, A. Mantovani, C. Maffeis, A. Colecchia, R. Villani, L. Rinaldi, E. Orsi, G. Pisano, L.E. Adinolfi, S. Fargion, A.L. Fracanzani
Nutrients, genetic factors, and their interaction in non-alcoholic fatty liver disease and cardiovascular disease
2020 R. Lombardi, F. Iuculano, G. Pallini, S. Fargion, A.L. Fracanzani
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease
2019 G. Tosetti, M. Primignani, V. La Mura, R. D'Ambrosio, E. Degasperi, N. Mezzina, M. Viganò, M. Rumi, A.L. Fracanzani, R. Lombardi, S. Fargion, M. Fraquelli, A. Aghemo, P. Lampertico
Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes : evidence in NAFLD patients and cell cultures
2019 M. Gomaraschi, A.L. Fracanzani, P. Dongiovanni, C. Pavanello, E. Giorgio, L. Da Dalt, G.D. Norata, L. Calabresi, D. Consonni, R. Lombardi, A. Branchi, S. Fargion